Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.
J Alzheimers Dis. 2011;24(1):125-36. doi: 10.3233/JAD-2010-100450.
The ability to predict cognitive deterioration in patients with dementia holds valuable potential for clinical trials and early intervention. This study identified cognitive domains deteriorating differentially over time as well as baseline predictors of subsequent cognitive decline in patients referred to a memory clinic. Twenty-six subjects with Alzheimer's disease (AD) and 43 subjects with Subjective Memory Impairment (SMI) were entered into a longitudinal study in which cognitive function was assessed at baseline and at 8-monthly intervals for 2 years, using a range of well-validated measures. Thirty-seven patients with depression and 39 healthy controls were also longitudinally assessed. AD was associated with disproportionate deterioration over time on general measures of cognitive function, multiple measures of mnemonic processing, mental fluency (letter and category), and aspects of motor speed. SMI showed restricted relative cognitive deterioration on general measures of cognitive function, on a subset of memory measures, and on letter but not category fluency. Secondary analysis showed that earliest detectable ADAS-cog and MMSE decline in AD was at 16 months, while several specific neuropsychological indices were sensitive as early as 8 months (graded naming test, semantic naming, and the category/letter fluency tests). In combination, baseline/early changes in cognitive performance, alongside clinical measures, predicted 48% of disease progression over two years in memory impaired patients as a whole. These findings have implications for identifying patients likely to benefit from disease modifying agents, and for designing, powering, enriching, and implementing future clinical trials. Follow-up studies in independent populations are needed to validate predictive algorithms identified.
预测痴呆患者认知能力下降的能力对于临床试验和早期干预具有重要意义。本研究确定了在一段时间内不同程度恶化的认知领域,以及在被转介到记忆诊所的患者中随后认知能力下降的基线预测因素。26 名阿尔茨海默病(AD)患者和 43 名主观记忆障碍(SMI)患者被纳入一项纵向研究,在 2 年内每 8 个月进行一次基线和认知功能评估,使用一系列经过充分验证的测量方法。37 名抑郁症患者和 39 名健康对照者也进行了纵向评估。AD 患者的一般认知功能、多种记忆处理测量、思维流畅性(字母和类别)和运动速度方面的认知功能随时间呈不成比例的恶化。SMI 显示一般认知功能测量、记忆测量子集以及字母但不是类别流畅性的相对认知功能受限恶化。二次分析表明,AD 患者最早可检测到的 ADAS-cog 和 MMSE 下降发生在 16 个月,而一些特定的神经心理学指标早在 8 个月时就很敏感(分级命名测试、语义命名和类别/字母流畅性测试)。综合来看,认知表现的基线/早期变化以及临床测量可以预测整个记忆障碍患者在两年内 48%的疾病进展。这些发现对于确定可能受益于疾病修饰剂的患者以及设计、增强、丰富和实施未来临床试验具有重要意义。需要在独立人群中进行随访研究来验证所确定的预测算法。